Britain’s competition regulator has been told to review its evidence against US drugmaker Pfizer and Flynn Pharma in the UK as it seeks to reinstate a record £90m fine for excessive drug pricing, reported The Financial Times.
The drugmakers have avoided paying the fine after winning an appeal against the Competition and Markets Authority’s decision in 2018. The CMA took the case to the Court of Appeal, which on Tuesday dismissed three of its four grounds of objection to the tribunal’s decision.
In its judgment the court said the CMA should reconsider evidence that the companies had abused their dominant position to increase prices as well as the scale of any fine. But the court agreed that it did not have to set a theoretical benchmark when assessing abuse in relation to pricing drugs.
The ruling comes after the CMA fined Flynn and Pfizer £90m four years ago for abusing their dominant market position by increasing the price of an anti-seizure drug, relied upon by 48,000 epilepsy patients in the UK, by 2,285 per cent overnight in 2012.
Featured News
EU Conducts First-Ever Raids on a Company Under Foreign Subsidies Regulation
Apr 23, 2024 by
CPI
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Federal Judge Nods at $418M Deal in Real Estate Antitrust Suit
Apr 23, 2024 by
CPI
Mexican Watchdog Probes Amazon and Mercado Libre Over Loyalty Bundles
Apr 23, 2024 by
CPI
Competition Commission of India to Probe AI Landscape for Competition
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI